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Abstract
Background:  Plasmodium vivax is the second most common species among malaria patients
diagnosed in Europe, but epidemiological and clinical data on imported P. vivax malaria are limited.
The TropNetEurop surveillance network has monitored the importation of vivax malaria into
Europe since 1999.
Objectives: To present epidemiological and clinical data on imported P. vivax malaria collected at
European level.
Material and methods: Data of primary cases of P. vivax malaria reported between January 1999
and September 2003 were analysed, focusing on disease frequency, patient characteristics, place of
infection, course of disease, treatment and differences between network-member countries.
Results: Within the surveillance period 4,801 cases of imported malaria were reported. 618
(12.9%) were attributed to P. vivax. European travellers and immigrants were the largest patient
groups, but their proportion varied among the reporting countries. The main regions of infection
in descending order were the Indian subcontinent, Indonesia, South America and Western and
Eastern Africa, as a group accounting for more than 60% of the cases. Regular use of malaria
chemoprophylaxis was reported by 118 patients. With 86 (inter-quartile range 41–158) versus 31
days (inter-quartile range 4–133) the median symptom onset was significantly delayed in patients
with chemoprophylaxis (p < 0.0001). Common complaints were fever, headache, fatigue, and
musculo-skeletal symptoms. All patients survived and severe clinical complications were rare.
Hospitalization was provided for 60% and primaquine treatment administered to 83.8% of the
patients, but frequencies varied strongly among reporting countries.
Conclusions: TropNetEurop data can contribute to the harmonization of European treatment
policies.
Introduction
Plasmodium vivax, has a major adverse impact on global
health [1], accounting for 70–80 million clinical cases
annually. It is responsible for over 50% of malaria outside
Africa, notably in Southeast Asia and Central and South
America, and particularly on the Indian subcontinent. It
also accounts for around 10% of cases in Eastern and
Southern Africa but has only limited prevalence in West
Africa, presumably due to the presence of Duffy-negative
blood group variants that limit erythrocyte invasion by
the parasite [2-5]. Similar to Plasmodium falciparum, P.
vivax may cause severe anaemia, but major complications
like cerebral malaria, hypoglycaemia, metabolic acidosis
and respiratory distress observed in P. falciparum malaria,
do not occur [3,6].
When imported to non-endemic areas, vivax malaria,
despite its uncomplicated course, requires special atten-
tion for two reasons. First, diagnosis often is complicated
by the late onset of symptoms which unlike those
observed in falciparum malaria, may occur several
months after arrival from endemic areas [7-10]. Second,
case management is complicated by the fact that parasites
can remain dormant in the liver as hypnozoites. Thus,
even if blood stages of the parasite are cleared, reactiva-
tion of these liver forms may cause relapses within a few
months [5,11].
Malaria is a notifiable disease in all European countries
[12]. As shown by national surveillance reports [13-19], P.
vivax  is presently the second most frequent cause of
imported malaria in most of Europe, except France [9,20],
accounting for up to 40% of the annual cases in single
countries. However, since P. vivax is less virulent than P.
falciparum [3,6], surveillance reports primarily focus on P.
falciparum infections. Epidemiological and clinical details
of imported P. vivax malaria are, therefore, hardly
described.
Since 1999, the importation of vivax malaria into Europe
has also been systematically monitored by the TropNetEu-
rop surveillance network. The present article summarises
epidemiological and clinical data of the disease collected
during the first 56 months of surveillance at European
level, focusing on disease frequency, patient characteris-
tics, place of infection, course of disease and treatment.
Differences between network-member countries are high-
lighted.
Patients, materials and methods
The European network TropNetEurop was founded in
1999 to effectively detect emerging infections of potential
regional, national or global impact at their point of entry
into the domestic population, to link clinical and epide-
miological knowledge and to serve as a platform forMalaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/5
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multi-centre research. Sentinel surveillance reporting is
carried out by participating sites by use of a standardised
and computerised reporting system. Electronic transmis-
sion of anonymous case information, comprising stand-
ardised demographic, epidemiological and clinical data,
to the central database assures rapid detection of sentinel
events. Presently 46 clinical sites from 16 European coun-
tries are organised in the network. Additional information
about TropNetEurop and the reporting instruments can
be received from the internet at http://www.tropnet.net.
The present work summarises data of primary cases of P.
vivax malaria reported within the network between Janu-
ary 1999 and September 2003. Relapse notifications were
excluded from the database to avoid multiple-counting of
importation events. Mixed-infections with P. vivax and
other Plasmodium species were included. However, while
analyses focusing on disease frequency, patient character-
istics and place of infection were based on all observa-
tions, analyses with clinical end point were restricted to
mono-infections elicited microscopically (confirmed
cases) or by antibody detection (probable cases) in order
to reduce bias. Patients with mixed plasmodial or other
concomitant infections, cases diagnosed by clinical rea-
soning (suspected cases) and cases reported without spec-
ification of the underlying diagnostic proof (unclassified
cases) were excluded from those analyses.
All analyses were done with the SAS software (release 8.01
by SAS Institute Inc., Cary, NC, USA). Missing values were
assumed to be non-systematic. Incomplete cases were
therefore disregarded in single calculations. However,
sample size or missing data information is given with each
result.
Results
Between January 1999 and September 2003, a total of
4,801 patients with travel-related malaria were reported
within the TropNetEurop network. P. vivax was involved
in 618 (12.9%) cases, either as sole pathogen (n = 585) or
in mixed-infections with other species (n = 33), thus
accounting for the second highest number of cases after P.
falciparum. The reported proportion of P. vivax was rather
steady with 10.9% in 1999, 12.6% in 2000, 15.1% in
2001, 12.3% in 2002 and 12.9% in 2003. All 16 TropNe-
tEurop countries reported P. vivax malaria. However, as
shown in table 1, the number of cases varied strongly
between countries. Germany (24.3%), Spain (15.5%) and
the UK (12.0%) reported most cases, whereas reports
from Switzerland (1.8%), Poland (1.6%), Finland
(1.0%), Ireland (1.0%) and Portugal (0.3%) were scarce.
According to diagnostic information 557 (90.1%) of the
618 infections were confirmed, two (0.3%) were probable
and eight (1.3%) were suspected cases. The remaining 51
(8.3%) could not be classified, due to missing informa-
tion on the underlying diagnostic procedure. Those and
the suspected cases were excluded from analyses with clin-
ical endpoints in the latter.
Table 1: Frequency of P. vivax malaria by year and reporting country
1999 2000 2001 2002 2003* Total
Country n (%) n (%) n (%) n (%) n (%) n (%)
Austria 2 (2.1) 8 (4.9) 5 (2.7) 5 (3.9) 3 (6.3) 23 (3.7)
Belgium 17 (10.4) 8 (4.3) 7 (5.5) 2 (4.2) 34 (5.5)
Czech Rep. 9 (9.6) 13 (7.9) 20 (10.8) 5 (3.9) 3 (6.3) 50 (8.1)
Denmark 14 (14.9) 16 (9.8) 12 (6.5) 5 (3.9) 1 (2.1) 48 (7.8)
Finland 1 (0.6) 6 (4.7) 6 (1.0)
France 1 (1.1) 1 (0.6) 4 (2.2) 7 (5.5) 2 (4.2) 15 (2.4)
Germany 31 (33.0) 35 (21.3) 51 (27.6) 22 (17.3) 11 (22.9) 150 (24.3)
Ireland 2 (1.2) 1 (0.5) 1 (0.8) 2 (4.2) 6 (1.0)
Italy 8 (8.5) 10 (6.1) 16 (8.6) 3 (2.4) 37 (6.0)
Norway 4 (2.2) 8 (6.3) 1 (2.1) 13 (2.1)
Poland 3 (3.2) 4 (2.2) 3 (2.4) 10 (1.6)
Portugal 1 (0.8) 1 (2.1) 2 (0.3)
Spain 15 (16.0) 31 (18.9) 23 (12.4) 23 (18.1) 4 (8.3) 96 (15.5)
Sweden 4 (4.3) 8 (4.9) 15 (8.1) 8 (6.3) 8 (16.7) 43 (7.0)
Switzerland 4 (4.3) 1 (0.6) 5 (3.9) 1 (2.1) 11 (1.8)
UK 3 (3.2) 22 (13.4) 22 (11.9) 18 (14.2) 9 (18.8) 74 (12.0)
Total 94 (100) 164 (100) 185 (100) 127 (100) 48 (100) 616 (100)
* Data reported between January and September 2003Malaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/5
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Table 2 describes characteristics of the 618 patients. About
2/3 were male. The median age was 32 years (inter-quar-
tile range 26–43). About 50% reported reception of pre-
travel advice, 42.2% stated use of anti-malarial chemo-
prophylaxis. Among those with prophylaxis, 62.1% stated
compliance with the recommended regimen.
The majority of patients who imported vivax malaria into
Europe were Europeans living and working in Europe
(66.0%). Immigrants and refugees, summarising both
those of overseas origin who may have lived in the report-
ing country for many years and very recent immigrants,
made up the second largest group (19.7%), followed by
European expatriates (8.5%) and foreign visitors (5.8%).
Analysing patient classifications by reporting country
revealed that immigrants and refugees accounted for dis-
tinctly more than the overall 20% proportion in Norway
(61.5%), Italy (45.9%), France (40.0%), Spain (31.3%)
and Denmark (25.0%).
Reasons for travel differed for Europeans and immigrants.
While Europeans living in Europe mainly travelled for
tourism (71.4%), followed by business (7.8%), mission-
ary work (7.0%), research (6.3%), visits to relatives or
friends (6.0%), military missions (0.8%) or other reasons
(0.8%). The main reasons for travel in the immigrant
group were immigration to Europe (47.0%) or visits to
relatives or friends in the former home country (44.4%).
Figure 1 marks 16 geographical regions from which P.
vivax malaria was imported from during the 56 month
surveillance period. The main regions of infection were
the Indian subcontinent (17.0%), Indonesia (12.1%),
South America (11.4%) and Western Africa (11.4%), as a
group accounting for 52% of the cases. However, while
the Indian subcontinent was the main region of infection
each year, the others switched places in the annual rank-
ing order. Further regions of importance were Eastern
Africa (10.0%), Southeast Asia (8.6%), and Oceania
(8.5%), contributing another 27% of the cases. Main
countries of infection were Indonesia (12.1%), India
(8.7%), Papua New Guinea (8.0%), Pakistan (7.8%) and
Ecuador (5.7%).
Exclusion of patients with concomitant plasmodial or
other infections and cases with suspected or unknown
diagnostic status left 526 patients for the analysis of clini-
cal endpoints. Symptom information was given for 487 of
those. The most frequent complaints were fever, head-
ache, fatigue and musculo-skeletal symptoms, affecting
95.5%, 51.3%, 32.6% and 29.6% of the patients, respec-
tively. However, a variety of other symptoms was noted,
too. Further information on the course of the disease is
summarised in table 3. The median time from end of jour-
ney to symptom onset was 60 days (inter-quartile range
8–149). However, with 86 versus 31 days the median
onset of symptoms was significantly delayed in patients
with chemoprophylaxis (p<0.0001 Wilcoxon rank test).
More than half of the patients (60.1%) were hospitalised,
although in-patient treatment was distinctly less common
in Ireland (0%), Switzerland (9.1%), Belgium (15.6%)
and Spain (26.1%). The median length of hospitalization
was four days (inter-quartile range 2–5). Information
whether complications occurred during the course of the
disease, was given for 270 of the 526 patients. Complica-
tions were reported in 30 of them, 22 mentioning recru-
descence or relapse, one G6PD-deficiency and seven
indicating severe disease. Specific complications in the lat-
ter group were serious spleno- or hepatomegaly (3
patients), spleen-rupture (1 patient), pancytopenia (1
patient), macrohaematuria (1 patient) and psychosis (1
patient). All 618 patients survived.
Treatment information was given for 518 confirmed and
probable mono-infections. Table 4 presents frequencies
of drugs used in the treatment of P. vivax malaria.
Although primaquine and chloroquine was the most fre-
quently used drug combination, 84 (16.2%) patients,
Table 2: Characteristics of patients with P. vivax malaria
N%
Sex (n = 615)
Male 422 68.6
Female 193 31.4
Pre-travel advice (n = 387)
Yes 208 53.7
No 179 46.3
Prophylaxis (n = 554)
None 320 57.8
Chloroquine 39 7.0
Proguanil 61 . 1
Proguanil + Chloroquine 45 8.1
Mefloquine 123 22.2
Doxycycline 12 2.2
Proguanil + Atovaquone 30 . 5
Other 61 . 1
Compliance (n = 190)
Yes 118 62.1
No 72 37.9
Patient classification (n = 615)
Immigrants/Refugees 121 19.7
Foreign visitors 36 5.8
Europeans living in EC 406 66.0
European expatriates 52 8.5
Median IQ-Range
Age (n = 606) 32 26–43
IQ-Range = Inter-quartile rangeMalaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/5
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including 61 males older than four, were not treated with
primaquine. Least frequent use of primaquine was
reported from France (0.0%), Ireland (20%), Poland
(40.0%) and Finland (50.0%).
Geographical origin of P. vivax malaria imported to Europe between January 1999 and September 2003 (n = 618) Figure 1
Geographical origin of P. vivax malaria imported to Europe between January 1999 and September 2003 (n = 618)
Table 3: Course of disease in 526 patients with confirmed or probable P. vivax mono-infection
Median IQ-Range
Days from end of journey to onset (nmiss = 80) 60 8–149
with chemoprophylaxis 86 41–158
without chemoprophylaxis 31 4–133
Days in hospital (nmiss = 400) 4 2–5
N % of non missing
In-patients (nmiss = 7) 312 60.1
Complications (nmiss = 256) 30 11.1
indicating treatment failure 23 8.5
indicating severe disease 72 . 6
Fatalities (nmiss = 0) 00 . 0
Nmiss= Number of cases disregarded due to missing data; IQ-Range = Inter-quartile rangeMalaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/5
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Discussion
Since network membership is self-selected, TropNetEurop
surveillance data may not be representative for the whole
of Europe. However, since most major referral centres of
the continent are represented in the network and the
number of patients treated within the network is large
(~62,000 patients/year), approximate representativeness
can be assumed. One objective of the present work was to
look at differences between TropNetEurop-member coun-
tries. However, since some countries contributed only
small numbers of cases to our database (see table 1) dif-
ferences found in between country comparisons should
rather be understood as hints than taken for proof.
According to TropNetEurop data, P. vivax is the second
most frequent cause of malaria importation, accounting
for 12.9% of the case imports into Europe since 1999.
Analysis of data from 612 patients treated for P. vivax
malaria in Europe between January 1999 and September
2003 yielded that 118 patients had contracted the disease
despite compliant chemoprophylaxis. However, since
standard chemoprophylactics do not act against hypno-
zoites [11,21-23], this does not indicate drug failure. Pri-
maquine, which acts against hypnozoites [11,21-24] and
was shown to be effective in the prevention of falciparum
and vivax malaria [25-27] has been proposed in North
America as an optional agent for regular or terminal
prophylaxis in certain travellers [23,28-30]. The fact that
primaquine prophylaxis was not reported in any of the
TropNetEurop cases reflects the fact that it is either very
effective, or uncommonly used in Europe. Most likely the
latter is true, since primaquine is presently not licensed for
prophylactic use. About half of the patients treated for
vivax malaria in Europe were Europeans, who contracted
the disease on holiday. Immigrants and refugees made up
the second largest patient group, with an overall propor-
tion of about 20%. In Norway, Italy, France, Spain and
Denmark they accounted for even more of the cases. The
fact that more than 40% of the immigrants had contracted
the disease on a visit to their former home country reveals
that even those who may have lived in Europe for many
still contribute considerably to malaria importation.
It seems peculiar that Western Africa was found to be a
major region of infection, accounting for more cases than
Eastern Africa. P. vivax prevalence was reported to be very
limited in Western Africa, due to the presence of Duffy-
negative blood-group variants [2-5]. Because our surveil-
lance data lack a true denominator it cannot be excluded,
that the larger number of patients returning from Western
Africa with vivax malaria results from higher travel activity
to that region. However, since international tourist arriv-
als counted by the world tourist organisation in 1999 and
2000 http://www.world-tourism.org were twice as high in
Eastern Africa, this appears to be an unlikely explanation.
Another hypothetical explanation would be that a major
part of the vivax cases reported from Western Africa might
be misclassified infections with Plasmodium ovale, which is
more common in that region and difficult to distinguish
from P. vivax microscopically.
Analysis of the course of the disease revealed that half of
the patients fell ill later than 60 days after arrival from an
endemic area. The most common complaints were fever,
headache, fatigue, and musculo-skeletal symptoms. The
finding that symptom onset was significantly delayed in
patients with chemoprophylaxis is consistent with
recently published findings [10]. This can be explained by
the activity of standard prophylactics against blood stages
but not against hypnozoites. No fatalities and only few
severe clinical complications were reported, which
emphasises P. vivax's limited virulence as compared to P.
falciparum [3,6]. More than half of the patients received in-
patient treatment, indicating differences in national treat-
ment policies rather than severe disease, since hospitaliza-
tion rates varied greatly among TropNetEurop member
countries.
None of the blood schizonticides used in the treatment of
malaria affects hypnozoites of P. vivax, thus radical cure
without relapses can only be achieved by additional
administration of primaquine [11,21,23,31]. However,
since P. vivax strains differ in their innate sensitivity to pri-
maquine, anti-relapse treatment may fail, especially when
underdosed [21,32-34]. On the other hand, omission of
antirelapse treatment does not necessarily lead to relapses
[35]. Both uncertainties might be used as an argument to
restrict primaquine use to the treatment of recurrent epi-
sodes of the disease, even in patients without G6PD-defi-
ciency [36]. Still, relapses may seriously threaten patients'
health, whereas primaquine, which is highly effective in
relapse prevention [31,32], is well tolerated [25-28]. This
indicates that unrestricted use of primaquine in patients
without G6PD-deficiency might offer additional health
Table 4: Drugs used in the treatment of 518 patients with P. vivax 
malaria
Drugs No. of patients %
Primaquine 434 83.8
Chloroquine 426 82.2
Quinine 48 9.3
Mefloquine 36 6.9
Atovaquone/Proguanil 12 2.3
Artemether/Lumefantrine 4 0.8
Proguanil 3 0.6
Artemisinin-derivates 2 0.4
Pyriniethamine/Sulfadoxine 1 0.2
Note. Multiple entries per patient were possibleMalaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/5
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benefits. However, this has not been evaluated in system-
atic risk benefit analyses. Our data on complications sup-
port the finding that primaquine treatment is well
tolerated but not perfectly preventive. Within the net-
work, 16.2% of the patients did not receive primary anti-
relapse treatment with primaquine. Contraindications
like G6PD-deficiency, young age or pregnancy could be
ruled out as an explanation in most of these cases [21].
Primaquine relapse prevention was found to be common
in most TropNetEurop member countries, with France,
Ireland, Poland, and Finland showing clearly lower utili-
zation of the drug. This indicates heterogeneity of
national or site-specific treatment policies. An inquiry
among members of TropNetEurop confirmed that some
sites actually do limit primaquine to the treatment of
recurrent episodes.
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